Chung Cheng-Han, Murphy Christopher M, Wingate Vincent P, Pavlicek Jeffrey W, Nakashima Reiko, Wei Wei, McCarty Douglas, Rabinowitz Joseph, Barton Erik
Pfizer Inc., Worldwide Research, Development and Medical, Bioprocess Research and Development, Morrisville, NC 27560, USA.
Pfizer Inc., Worldwide Research, Development and Medical, Simulation and Modeling Sciences, Cambridge, MA 02139, USA.
Mol Ther Methods Clin Dev. 2023 Jan 16;28:272-283. doi: 10.1016/j.omtm.2023.01.002. eCollection 2023 Mar 9.
Recombinant adeno-associated virus (rAAV) is a clinically proven viral vector for delivery of therapeutic genes to treat rare diseases. Improving rAAV manufacturing productivity and vector quality is necessary to meet clinical and commercial demand. These goals will require an improved understanding of the cellular response to rAAV production, which is poorly defined. We interrogated the kinetic transcriptional response of HEK293 cells to rAAV production following transient plasmid transfection, under manufacturing-relevant conditions, using RNA-seq. Time-series analyses identified a robust cellular response to transfection and rAAV production, with 1,850 transcripts differentially expressed. Gene Ontology analysis determined upregulated pathways, including inflammatory and antiviral responses, with several interferon-stimulated cytokines and chemokines being upregulated at the protein level. Literature-based pathway prediction implicated multiple pathogen pattern sensors and signal transducers in up-regulation of inflammatory and antiviral responses in response to transfection and rAAV replication. Systematic analysis of the cellular transcriptional response to rAAV production indicates that host cells actively sense vector manufacture as an infectious insult. This dataset may therefore illuminate genes and pathways that influence rAAV production, thereby enabling the rational design of next-generation manufacturing platforms to support safe, effective, and affordable AAV-based gene therapies.
重组腺相关病毒(rAAV)是一种经临床验证的病毒载体,可用于递送治疗基因以治疗罕见疾病。提高rAAV的生产效率和载体质量对于满足临床和商业需求至关重要。要实现这些目标,需要更好地了解细胞对rAAV生产的反应,而目前对此了解甚少。我们在与生产相关的条件下,通过RNA测序研究了瞬时质粒转染后HEK293细胞对rAAV生产的动力学转录反应。时间序列分析确定了细胞对转染和rAAV生产的强烈反应,有1850个转录本差异表达。基因本体分析确定了上调的途径,包括炎症和抗病毒反应,几种干扰素刺激的细胞因子和趋化因子在蛋白质水平上上调。基于文献的途径预测表明,多种病原体模式传感器和信号转导器参与了对转染和rAAV复制的炎症和抗病毒反应的上调。对细胞对rAAV生产的转录反应的系统分析表明,宿主细胞将载体生产主动感知为一种感染性刺激。因此,该数据集可能会揭示影响rAAV生产的基因和途径,从而有助于合理设计下一代生产平台,以支持安全、有效且经济实惠的基于AAV的基因疗法。